ChiCTR2500098068
尚未开始
/
/
/
2025-03-03
/
/
Depression
Exploring the augmentative effects and mechanisms of integrating computerized cognitive training with transcranial magnetic stimulation in late-life depression: a proof-of-concept randomized controlled trial
Exploring the augmentative effects and mechanisms of integrating computerized cognitive training with transcranial magnetic stimulation in late-life depression: a proof-of-concept randomized controlled trial
1. The primary objective is to examine the effect of combined rTMS and CCT on changes in depressive symptoms. 2. The secondary objective is to examine the effect of combined rTMS and CCT on changes in mood, cognition, level of functioning, functional brain networks, cortical excitability, and serum BDNF levels.
随机平行对照
其它
Participants will be randomly assigned to either the intervention or control group in a 1:1 ratio using a central computer-generated random number sequence.
No one, except the RA who sets up the CCT station, will know the group assignments. Participants will not know their group or the exact CCT setting, and they will be asked not to discuss their treatment with others. The rTMS operator and the RA who prepares the CCT station will not assess outcomes. Outcome assessors will be blinded to group assignments and not involved in intervention delivery.
Research Grants Council
/
60
/
2025-03-01
2028-12-31
/
Ethnic Chinese; aged 55 to 75 years; right-handed; living at home; having a primary diagnosis of major depressive disorder (single or recurrent episodes without psychotic features) based on DSM-5 criteria; current episode scoring >17 in the Hong Kong Chinese version of the 17-item Hamilton Rating Scale for Depression (HAM-D), with cognitive symptoms [Item 8 in HAM-D (slowness of thought and speech, impaired ability to concentrate) scoring ≥2]; not responding to an adequate dose of an antidepressant; and having received a stable antidepressant regimen for at least 4 weeks before joining this trial.；
登录查看Alcohol or substance abuse; bipolar disorder; any psychotic disorder or current psychotic symptoms; dementia; active suicidal ideation; anxiety disorder; personality disorder; mental disorder due to organic cause; neurological disorders (Parkinson’s disease, stroke, brain tumor); and unstable physical illness. Individuals identified with these conditions will be excluded and referred to the Hospital Authority for further management. Other exclusion criteria are: history of seizure or epilepsy; contraindications to magnetic resonance imaging (MRI); metallic implants in cephalic region (including aneurysm clips, shuts, stimulators, cochlear implant, or electrodes); history of receiving non-invasive brain stimulation (TMS, tDCS, tACS, etc.), electroconvulsive therapy, cognitive training, or psychological intervention in the past 6 months; refusing blood taking or MRI; or having language barrier or communication impairments (poor vision and hearing despite correction).；
登录查看The Chinese University of Hong Kong
/
BioArtMED2025-04-27
Insight数据库2025-04-27
Insight数据库2025-04-27
抗体圈2025-04-27
正大天晴药业集团2025-04-27
医麦客2025-04-27
精准药物2025-04-27
莱芒生物2025-04-26
尧唐生物2025-04-26
尧唐生物2025-04-26
18983288589（微信同号）
18983288589（微信同号）
18908392210（微信同号）
18980413049
浙公网安备33011002015279
© pharnexcloud.com 2025 YAORONGYUN All Rights Reserved.
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
